Teriparatide (Forteo): Clinical Overview for Providers

Teriparatide, marketed as Forteo, is recombinant human parathyroid hormone (1-34) — the biologically active fragment of PTH. It was the first anabolic osteoporosis therapy, meaning it stimulates new bone formation rather than merely slowing bone loss. It is one of the most clinically substantial peptides in this entire formulary.

This guide situates Teriparatide within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

The parathyroid hormone paradox

Chronic elevation of parathyroid hormone is a classic cause of bone loss. In primary hyperparathyroidism, sustained PTH excess drives osteoclastic resorption, cortical thinning and fracture. Every clinician learns PTH as a bone-destroying hormone.

Give the same hormone as a single daily injection and the outcome reverses: bone formation markers rise before resorption markers, osteoblast activity is favored, and bone mass increases. The difference is not the molecule or the total dose — it is the pattern of exposure.

The mechanistic explanation centers on the transient nature of the signal. A brief daily pulse favors osteoblast survival and activity, opening a window in which formation outpaces resorption. Continuous exposure shifts the balance toward RANKL-mediated osteoclastic activity. This is the same intermittent-versus-continuous principle that governs GnRH and the growth hormone axis, and it is the single most transferable concept in peptide pharmacology.

What the evidence shows

The pivotal trial in postmenopausal women with prior vertebral fracture demonstrated substantial reductions in new vertebral fractures and significant reductions in nonvertebral fractures, alongside marked increases in lumbar spine bone mineral density.

Teriparatide is indicated for postmenopausal women and men with osteoporosis at high fracture risk, and for men and women with glucocorticoid-induced osteoporosis at high risk. In head-to-head work against oral bisphosphonate in glucocorticoid-induced disease, it produced greater BMD gains and fewer vertebral fractures.

Bone gain is not uniform across the skeleton. Lumbar spine responds most, hip more modestly, and cortical sites such as the distal radius may show little change or transient decline — an expected pattern reflecting increased cortical porosity during remodeling, not treatment failure.

Why treatment sequence matters

Two facts make sequencing decisions consequential rather than academic.

First, the gains are not durable alone. Bone density declines after teriparatide is stopped. An antiresorptive agent must follow — a bisphosphonate or denosumab — to consolidate what was built. Stopping without follow-on therapy forfeits much of the benefit.

Second, order changes the result. Anabolic therapy given first, followed by an antiresorptive, produces greater bone density gains than the reverse sequence. Prior potent antiresorptive treatment blunts the anabolic response. Most importantly, transitioning from denosumab directly to teriparatide can produce transient bone loss, and denosumab discontinuation carries a well-described risk of rapid loss and multiple vertebral fractures. That transition requires specialist planning.

Historical restrictions on cumulative treatment duration, and the earlier boxed warning regarding osteosarcoma observed in rats, have been revised as post-marketing data accumulated without a corresponding human signal. Current labeling should be consulted rather than remembered.

Safety and practical considerations

Common effects include transient hypercalcemia, nausea, headache, leg cramps and orthostatic symptoms, particularly after early doses — patients should take the first several injections where they can sit or lie down.

Baseline calcium and vitamin D status should be assessed and corrected, since an anabolic agent demands substrate. Serum calcium, renal function and vitamin D warrant monitoring. Caution applies in patients with prior skeletal radiation, active malignancy involving bone, unexplained elevated alkaline phosphatase, or metabolic bone disease other than osteoporosis.

Teriparatide requires refrigeration and daily self-injection, which are real adherence considerations. Cost has historically been a barrier, though biosimilar availability has changed that picture in some settings.

It belongs to patients at genuinely high fracture risk, and identifying those patients is the clinically decisive step.